Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice

被引:257
|
作者
Denton, Paul W. [1 ]
Estes, Jacob D. [2 ]
Sun, Zhifeng [1 ]
Othieno, Florence A. [1 ]
Wei, Bangdong L. [1 ]
Wege, Anja K. [1 ]
Powell, Daniel A. [1 ]
Payne, Deborah [3 ]
Haase, Ashley T. [2 ]
Garcia, J. Victor [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Div Infect Dis, Dept Internal Med, Dallas, TX 75390 USA
[2] Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA
来源
PLOS MEDICINE | 2008年 / 5卷 / 01期
关键词
D O I
10.1371/journal.pmed.0050016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Worldwide, vaginal transmission now accounts for more than half of newly acquired HIV-1 infections. Despite the urgency to develop and implement novel approaches capable of preventing HIV transmission, this process has been hindered by the lack of adequate small animal models for preclinical efficacy and safety testing. Given the importance of this route of transmission, we investigated the susceptibility of humanized mice to intravaginal HIV-1 infection. Methods and Findings We show that the female reproductive tract of humanized bone marrow - liver - thymus (BLT) mice is reconstituted with human CD4(+) T and other relevant human cells, rendering these humanized mice susceptible to intravaginal infection by HIV-1. Effects of HIV-1 infection include CD4(+) T cell depletion in gut-associated lymphoid tissue (GALT) that closely mimics what is observed in HIV-1 - infected humans. We also show that pre-exposure prophylaxis with antiretroviral drugs is a highly effective method for preventing vaginal HIV-1 transmission. Whereas 88% (7/8) of BLT mice inoculated vaginally with HIV-1 became infected, none of the animals (0/5) given pre-exposure prophylaxis of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) showed evidence of infection (Chi square 7.5, df 1, p=0.006). Conclusions The fact that humanized BLT mice are susceptible to intravaginal infection makes this system an excellent candidate for preclinical evaluation of both microbicides and pre-exposure prophylactic regimens. The utility of humanized mice to study intravaginal HIV-1 transmission is particularly highlighted by the demonstration that pre-exposure prophylaxis can prevent intravaginal HIV-1 transmission in the BLT mouse model.
引用
收藏
页码:79 / 89
页数:11
相关论文
共 50 条
  • [41] Enhanced Selection for HIV-1 Transmitted/Founder Viruses in BLT Humanized Mice Following Intravaginal Exposure
    Claiborne, Daniel
    Deymier, Martin
    Tully, Damien
    Power, Karen
    Krupp, Katharine
    Phelps, Meredith
    Trifonova, Radiana
    Vrbanac, Vladimir
    Deruaz, Maud
    Boutwell, Christian
    Hunter, Eric
    Allen, Todd
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 : 400 - 400
  • [42] Recreational Use of HIV Antiretroviral Medication and Implications for HIV Pre-exposure Prophylaxis and Treatment
    Caroline Kuo
    Danielle Giovenco
    Teresa DeAtley
    Jackie Hoare
    Kristen Underhill
    Millicent Atujuna
    Catherine Mathews
    Dan J. Stein
    Larry K. Brown
    Don Operario
    [J]. AIDS and Behavior, 2020, 24 : 2650 - 2655
  • [43] Detection of new HIV infections in a multicentre HIV antiretroviral pre-exposure prophylaxis trial
    Fransen, Katrien
    de Baetselier, Irith
    Rammutla, Elizabeth
    Ahmed, Khatija
    Owino, Frederick
    Agingu, Walter
    Venter, Gustav
    Deese, Jen
    Van Damme, Lut
    Crucitti, Tania
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2017, 93 : 76 - 80
  • [44] Pre-clinical evaluation of antiproteases as potential candidates for HIV-1 pre-exposure prophylaxis
    Herrera, Carolina
    Olejniczak, Natalia
    Noel-Romas, Laura
    Plummer, Frank
    Burgener, Adam
    [J]. FRONTIERS IN REPRODUCTIVE HEALTH, 2022, 4
  • [45] Vaginal dysbiosis and pre-exposure prophylaxis efficacy
    van de Wijgert, Janneke
    McCormack, Sheena
    [J]. LANCET HIV, 2017, 4 (10): : E427 - E429
  • [46] Pre-Exposure Prophylaxis for HIV Upfront
    de Mendoza, Carmen
    [J]. AIDS REVIEWS, 2011, 13 (01) : 57 - 58
  • [47] Pre-Exposure Prophylaxis and HIV Incidence
    Mann, Samuel
    [J]. B E JOURNAL OF ECONOMIC ANALYSIS & POLICY, 2023, 23 (04): : 1163 - 1173
  • [48] Modeling HIV Pre-Exposure Prophylaxis
    Straubinger, Thomas
    Kay, Katherine
    Bies, Robert
    [J]. FRONTIERS IN PHARMACOLOGY, 2020, 10
  • [49] HIV moments and pre-exposure prophylaxis
    Grant, Robert M.
    Glidden, David V.
    [J]. LANCET, 2016, 387 (10027): : 1507 - 1508
  • [50] Prescribing pre-exposure prophylaxis for HIV
    Bloch, Mark
    [J]. AUSTRALIAN PRESCRIBER, 2020, 43 (06) : 200 - 203